Bevacizumab-Induced Inhibition of Angiogenesis Promotes a More Homogeneous Intratumoral Distribution of Paclitaxel, Improving the Antitumor Response.
about
Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics3D Mass Spectrometry Imaging Reveals a Very Heterogeneous Drug Distribution in Tumors.A Nanostructured Matrices Assessment to Study Drug Distribution in Solid Tumor Tissues by Mass Spectrometry Imaging.Drug delivery in a tumour cord model: a computational simulationLimited Tumor Tissue Drug Penetration Contributes to Primary Resistance against Angiogenesis InhibitorsHeterogeneity of paclitaxel distribution in different tumor models assessed by MALDI mass spectrometry imaging.Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial.Vessel pruning or healing: endothelial metabolism as a novel target?Orthotopic Model of Ovarian Cancer.MALDI mass spectrometry imaging of erlotinib administered in combination with bevacizumab in xenograft mice bearing B901L, EGFR-mutated NSCLC cells.Revisiting Bevacizumab + Cytotoxics Scheduling Using Mathematical Modeling: Proof of Concept Study in Experimental Non-Small Cell Lung Carcinoma.Endoscopic non-ablative fractional laser therapy in an orthotopic colon tumour model.Molecular and Pharmacological Mechanisms of Drug Resistance:An Evolving Paradigm.Distribution of erlotinib in rash and normal skin in cancer patients receiving erlotinib visualized by matrix assisted laser desorption/ionization mass spectrometry imaging.MR imaging biomarkers evaluating vascular normalization window after anti-vessel treatment.Treatment response assessment with (R)-[11CPAQ PET in the MMTV-PyMT mouse model of breast cancer.
P2860
Q26746067-55BF6C93-6EA2-4965-9146-78DB97B0A5CEQ30828511-4588CC8D-ACA1-47AD-A686-D13FD97BC05DQ33553411-BE52FD02-A908-46F4-BD7D-0F6756B1C3C4Q33748082-D1C8E30A-1DB8-4871-B38B-9DF163F9CE6CQ36237312-24705C0A-EC8A-495A-B489-EAC7D4A88339Q37522770-9A50BEA8-0857-470D-B737-3AE091351C88Q38854993-7341CFF7-DFCF-479D-8FEF-F17F696B3902Q39024164-DEAE111D-5580-45C0-85E0-98BF653C27E5Q39178435-DBE0D58C-23F9-4853-9823-7FBD360A1042Q47114407-49E0184B-4F04-4B39-A125-0272A6B9AA23Q47346043-F21FB3F7-9D00-41CA-876A-63CCF61DF7ADQ47709443-623FA425-BDE2-45EB-B9C7-4B52A18F880BQ53746575-350D91E8-93DC-4389-A02D-52A8711622BBQ54979887-E1413C8E-7BBC-425B-B97C-7EC036AEB50BQ55194814-944EE090-3EF4-4898-95F9-092440EDA7C4Q55262619-B5C58C09-9103-4B9D-85CC-24C5FD7E9FE9
P2860
Bevacizumab-Induced Inhibition of Angiogenesis Promotes a More Homogeneous Intratumoral Distribution of Paclitaxel, Improving the Antitumor Response.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Bevacizumab-Induced Inhibition ...... roving the Antitumor Response.
@ast
Bevacizumab-Induced Inhibition ...... roving the Antitumor Response.
@en
type
label
Bevacizumab-Induced Inhibition ...... roving the Antitumor Response.
@ast
Bevacizumab-Induced Inhibition ...... roving the Antitumor Response.
@en
prefLabel
Bevacizumab-Induced Inhibition ...... roving the Antitumor Response.
@ast
Bevacizumab-Induced Inhibition ...... roving the Antitumor Response.
@en
P2093
P50
P1476
Bevacizumab-Induced Inhibition ...... proving the Antitumor Response
@en
P2093
Alexander Berndt
Edoardo Micotti
Ilaria Fuso Nerini
Marta Cesca
Olaf Dirsch
Petra Richter
Silvia Giordano
P304
P356
10.1158/1535-7163.MCT-15-0063
P50
P577
2015-10-22T00:00:00Z